Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

ClinicalTrials.gov ID: NCT03617536

Public ClinicalTrials.gov record NCT03617536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of 3 dose levels of oral CR845 compared to placebo in reducing the intensity of itch in chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study will consist of a Screening Period, a 7-day Run-in Period, a 12 week Treatment Period, and a Follow-up Visit (approximately 7 days after the last dose of study drug).

Study identification

NCT ID
NCT03617536
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cara Therapeutics, Inc.
Industry
Enrollment
269 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 4, 2018
Primary completion
Oct 23, 2019
Completion
Nov 13, 2019
Last update posted
Jan 23, 2024

2018 – 2019

United States locations

U.S. sites
60
U.S. states
24
U.S. cities
55
Facility City State ZIP Site status
Cara Therapeutics Study Site Birmingham Alabama 35233
Cara Therapeutics Study Site Florence Alabama 35630
Cara Therapeutics Study Site Phoenix Arizona 85016
Cara Therapeutics Study Site Prescott Arizona 86401
Cara Therapeutics Study Site Sun City Arizona 85351
Cara Therapeutics Study Site Harrisburg Arkansas 72432
Cara Therapeutics Study Site Bakersfield California 93309
Cara Therapeutics Study Site 2 Bakersfield California 99309
Cara Therapeutics Study Site Canyon Country California 91351
Cara Therapeutics Study Site Escondido California 92025
Cara Therapeutics Study Site Lomita California 90717
Cara Therapeutics Study Site Northridge California 91324
Cara Therapeutics Study Site Riverside California 92505
Cara Therapeutics Study Site Sacramento California 95831
Cara Therapeutics Study Site Whittier California 90602
Cara Therapeutics Study Site Denver Colorado 80230
Cara Therapeutics Study Site Washington D.C. District of Columbia 20037
Cara Therapeutics Study Site Edgewater Florida 32132
Cara Therapeutics Study Site Hialeah Florida 33016
Cara Therapeutics Study Site Hollywood Florida 33024
Cara Therapeutics Study Site Lake Worth Florida 33467
Cara Therapeutics Study Site 1 Miami Florida 33125
Cara Therapeutics Study Site 2 Miami Florida 33155
Cara Therapeutics Study Site Ocala Florida 34471
Cara Therapeutics Study Site Orlando Florida 32810
Cara Therapeutics Study Site Tampa Florida 33614
Cara Therapeutics Study Site Temple Terrace Florida 33637
Cara Therapeutics Study Site Augusta Georgia 30909
Cara Therapeutics Study Site Sandy Springs Georgia 30328
Cara Therapeutics Study Site Crystal Lake Illinois 60012
Cara Therapeutics Study Site Evanston Illinois 60201
Cara Therapeutics Study Site Iowa City Iowa 52242
Cara Therapeutics Study Site Metairie Louisiana 70006
Cara Therapeutics Study Site New Orleans Louisiana 70115
Cara Therapeutics Study Site Zachary Louisiana 70791
Cara Therapeutics Study Site Baltimore Maryland 21287
Cara Therapeutics Study Site Takoma Park Maryland 20912
Cara Therapeutics Study Site Flint Michigan 48503
Cara Therapeutics Study Site 2 Flint Michigan 48532
Cara Therapeutics Study Site Roseville Michigan 48066
Cara Therapeutics Study Site Saint Clair Michigan 48081
Cara Therapeutics Study Site Kansas City Missouri 64111
Cara Therapeutics Study Site Brooklyn New York 11229
Cara Therapeutics Study Site Mineola New York 11501
Cara Therapeutics Study Site Rocky Mount North Carolina 27804
Cara Therapeutics Study Site Columbus Ohio 43215
Cara Therapeutics Study Site Norman Oklahoma 73071
Cara Therapeutics Study Site Camp Hill Pennsylvania 17011
Cara Therapeutics Study Site Providence Rhode Island 02903
Cara Therapeutics Study Site Warwick Rhode Island 02886
Cara Therapeutics Study Site Greenville South Carolina 29605
Cara Therapeutics Study Site Rapid City South Dakota 57702
Cara Therapeutics Study Site Corsicana Texas 75110
Cara Therapeutics Study Site Gonzales Texas 78629
Cara Therapeutics Study Site Houston Texas 77074
Cara Therapeutics Study Site Houston Texas 77081
Cara Therapeutics Study Site Plano Texas 75093
Cara Therapeutics Study Site San Antonio Texas 78207
Cara Therapeutics Study Site San Antonio Texas 78224
Cara Therapeutics Study Site Alexandria Virginia 22304

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03617536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 23, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03617536 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →